{"analyses":[{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.51","estimateComment":"Hazard ratios were estimated by Cox regression model. Stratification factors: Binet and Geographic region.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.33","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"31.1","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause. Disease progression was characterized by at least one of the following: 1) \\>/= 50% increase in the absolute number of circulating lymphocytes to at least 5\\*10\\^9/L, 2) Appearance of new palpable lymph nodes (\\> 15 mm in longest diameter) or any new extra-nodal lesion; 3) \\>/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) \\>/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles comprised 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression or death up to approximately 3.75 years","title":"Progression Free Survival (PFS) Based on Institutional Review Committee (IRC)-Assessments According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria","type":"SECONDARY","unitOfMeasure":"months"}